Exceptional Power

AKYNZEO® prevents 90% of
CINV events over 5 days1

Complete response (no emesis and no use of rescue medication) for 5 days1

Overall Efficacy Chart
  • 90% complete response demonstrated over 5 days with AKYNZEO compared to 77% for oral palonosetron1
Primary endpoint: complete response in overall phase (0-120 hours)2
  • Complete response = no emesis and no use of rescue medications. This means that no rescue antiemetic agent was administered through 5 days2
Study design in patients receiving high-dose cisplatin1
Multicenter, randomized, double-blind, double-dummy, parallel-group study evaluating AKYNZEO (300 mg netupitant/0.5 mg palonosetron) (n=135) vs oral palonosetron (n=136)
  • Day 1: AKYNZEO + dexamethasone 12 mg vs palonosetron 0.5 mg + dexamethasone 20 mg
  • Days 2-4: Dexamethasone 8 mg once a day vs dexamethasone 8 mg twice a day
Patients received cisplatin (≥50 mg/m2 either alone or in combination with other chemotherapy agents)2
  • Patients received a high dose of cisplatin; without prophylaxis, this gives them more than a 90% risk of developing CINV3
  • 86% of AKYNZEO patients received concomitant chemotherapy along with cisplatin, potentially further increasing their risk of emetic events2,3
  • Median cisplatin dose: 75 mg/m2 for each group2

Patients treated with AKYNZEO primarily had a diagnosis of lung/respiratory cancer (25.9%), head and neck cancer (24.4%), or ovarian cancer (17.8%)2

CINV=chemotherapy-induced nausea and vomiting.